Re-evaluation of axillary skip metastases in the era of sentinel lymph node biopsy in breast cancer

被引:22
作者
Keskek, Mehmet
Balas, Sener
Gokoz, Aytac
Sayek, Iskender
机构
[1] Ankara Numune Training & Res Hosp, Dept Surg 5, Ankara, Turkey
[2] Univ Hacettepe Hosp, Dept Gen Surg, Ankara, Turkey
[3] Univ Hacettepe Hosp, Dept Pathol, Ankara, Turkey
关键词
breast cancer; axillary treatment; skip metastasis; micrometastasis;
D O I
10.1007/s00595-006-3322-6
中图分类号
R61 [外科手术学];
学科分类号
摘要
Purpose. To investigate whether skip axillary metastases are really skip metastases or a continuation of level I micrometastases in invasive breast cancer, and to determine whether there are any factors predisposing to skip metastases. Methods. We reviewed 568 consecutive patients with breast cancer who underwent complete axillary lymph node dissections (ALND) between January 1998 and December 2004. For patients with skip axillary lymph node metastases, resectioning and immunohistochemical staining of the remaining part of paraffin blocks from level I lymph nodes were done to determine whether there were any micrometastases in this group of lymph nodes. Results. Skip axillary metastases were found in 27 (10%) of 268 patients with axillary lymph node metastases. Re-evaluation of the level I lymph nodes, both with thin sectioning and immunohistochemical staining, in the patients with axillary skip metastases revealed no micrometastases. No significant correlation was found between the demographic and histopathological variables of the patients with skip metastases and those with regular axillary metastases. Conclusions. These results suggest that skip axillary metastases are actual skip metastases, not a continuation of undetected level I micrometastases. Moreover, none of the clinical and histopathological measures of primary tumors are predictors of the presence of skip metastases.
引用
收藏
页码:1047 / 1052
页数:6
相关论文
共 45 条
  • [1] Altinyollar H, 2000, J EXP CLIN CANC RES, V19, P141
  • [2] Clinical behavior of untreated axillary nodes after local treatment for primary breast cancer
    Baxter, N
    McCready, D
    Chapman, JA
    Fish, E
    Kahn, H
    Hanna, W
    Trudeau, M
    Lickley, HL
    [J]. ANNALS OF SURGICAL ONCOLOGY, 1996, 3 (03) : 235 - 240
  • [3] BERG JW, 1955, CANCER, V8, P776, DOI 10.1002/1097-0142(1955)8:4<776::AID-CNCR2820080421>3.0.CO
  • [4] 2-B
  • [5] Cady B, 1997, J SURG ONCOL, V66, P7, DOI 10.1002/(SICI)1096-9098(199709)66:1<7::AID-JSO3>3.0.CO
  • [6] 2-8
  • [7] NEW THERAPEUTIC POSSIBILITIES IN PRIMARY INVASIVE BREAST-CANCER
    CADY, B
    STONE, MD
    WAYNE, J
    [J]. ANNALS OF SURGERY, 1993, 218 (03) : 338 - 349
  • [8] Clinical outcome of patients with lymph node-negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry
    Chagpar, A
    Middleton, LP
    Sahin, AA
    Meric-Bernstam, F
    Kuerer, HM
    Feig, BW
    Ross, MI
    Ames, FC
    Singletary, SE
    Buchholz, TA
    Valero, V
    Hunt, KK
    [J]. CANCER, 2005, 103 (08) : 1581 - 1586
  • [9] Factors predicting failure to identify a sentinel lymph node in breast cancer
    Chagpar, AB
    Martin, RC
    Scoggins, CR
    Carlson, DJ
    Laidley, AL
    El-Eid, SE
    McGlothin, TQ
    Noyes, RD
    Ley, PB
    Tuttle, TM
    McMasters, KM
    [J]. SURGERY, 2005, 138 (01) : 56 - 63
  • [10] Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection?
    Chu, KU
    Turner, RR
    Hansen, NM
    Brennan, MB
    Bilchik, A
    Giuliano, AE
    [J]. ANNALS OF SURGERY, 1999, 229 (04) : 536 - 541